Debio 0432 / Novo Nordisk, Debiopharm - LARVOL DELTA

Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors (ESMO 2024) - "Here, we show that the inhibition of USP1 through Debio 0432 potentiates the effect of PARPi across several tumor types in vitro and in vivo. Furthermore, Debio 0432 has the potential to overcome PARPi resistance, as demonstrated by sensitization of resistant models to the combination of both compounds. Debio 0432 is currently undergoing IND-enabling studies and is poised to enter clinical development later in 2024."

Combination therapy • Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • BRCA • BRCA1 • PCNA • USP1

Identification of Debio 0432 as a potent and selective USP1 inhibitor for cancer therapy (AACR 2024) - "Overall, we show that Debio 0432 is a selective and potent small molecule targeting USP1, an emerging target in the DDR field. It shows good activity in different preclinical models and is well tolerated at active doses. Debio 0432 is currently undergoing IND-enabling studies and in preparation for entry into clinical development."

Breast Cancer • Oncology • Solid Tumor • BRCA • PCNA • USP1

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego (Businesswire) - "Debiopharm...today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California."

Preclinical • Breast Cancer • Oncology • Solid Tumor

Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432 (Businesswire) - "Ubiquigent Limited (Ubiquigent)...announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases. The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432. Under the terms of the agreement, Ubiquigent will deploy its DUB-focused platform, combined with its deep understanding of the DUB field, to develop novel target engagement assays to support Debio-0432 as it approaches the clinic."

Licensing / partnership • Oncology

DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY (PRNewswire) - "Debiopharm...announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk....FT-3171 (Debio 0432) could potentially be deployed to combat multiple tumor types in poly ADP ribose pathway inhibitor-sensitive and resistant settings."

Pipeline update • Oncology